196
Participants
Start Date
April 27, 2018
Primary Completion Date
April 30, 2023
Study Completion Date
December 31, 2026
whole pelvic radiotherapy
addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
metastasis-directed treatment
stereotactic body radiotherapy
salvage Lymph Node Dissection
metastasis-directed treatment
androgen deprivation therapy
LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
University Hospital Ghent, Ghent
Epworth Healthcare, Melbourne
GZA, Antwerp
AZ St-Jan Brugge, Bruges
AZ St-Lucas, Bruges
Institut Jules Bordet, Brussels
AZ Maria Middelares, Ghent
AZ Groeninge, Kortrijk
UZ Leuven, Leuven
CH Mouscron, Mouscron
Humanitas Research Hospital, Milan
Vita-Salute San Raffaele University, Milan
Istituto Nazionale Tumori IRCCS, Napoli
Fondazione IRCCS Policlinico S. Matteo, Pavia
Ospedale Sacro Cuore-Don Calabria, Verona
Oslo University Hospital, Oslo
Cruces University Hospital, Barakaldo
Clínica Universitaria IMQ, Bilbao
Hospital Ramón y Cajal, Madrid
Hospital Universitario La Princesa, Madrid
Universitario Quironsalud, Madrid
Hospitalario de Navarra, Navarro
Hospital Clínico de Santiago, Santiago
Hospital Universitari i Politècnic la Fe, Valencia
Universitätsspital Basel, Basel
Universitätsklinik für Radio-Onkologie, Bern
Hôpitaux Universitaires de Genève, Geneva
Kantonsspital St. Gallen, Sankt Gallen
UniversitätsSpital Zürich, Zurich
University Hospital, Geneva
OTHER
University Hospital, Ghent
OTHER